Neovasc Inc. Selling, General and Administrative Expense of Revenue

Selling, General and Administrative Expense of Revenue of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative Expense of Revenue for the quarter ending March 31, 2022 was 625.9% (a 128.87% increase compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative Expense of Revenue decreased by -12.9%
  • Annual Selling, General and Administrative Expense of Revenue for 2021 was 701.94% (a -10.8% decrease from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2020 was 786.95% (a 54.19% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2019 was 510.38% (a -21.0% decrease from previous year)
  • Twelve month Selling, General and Administrative Expense of Revenue ending March 31, 2022 was 512.95% (a -17.95% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative Expense of Revenue decreased by -40.19% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
512.95% 625.15% 755.73% 857.61%
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative Expense of Revenue of Neovasc Inc.

Most recent Selling, General and Administrative Expense of Revenueof NVCN including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative Expense of Revenue of Neovasc Inc.

Neovasc Inc. Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 625.9%
2021 273.47% 487.97% 718.59% 1290.67% 701.94%
2020 693.68% 820.83% 1506.34% 570.65% 786.95%
2019 561.01% 515.14% 649.69% 520.52% 510.38%
2018 1152.16% 1361.85% 607.6% 810.83% 646.08%
2017 695.62% 154.05% 189.84% 231.94% 261.04%
2016 94.28% 121.15% 444.7% 298.61% 208.98%
2015 169.96% 188.46% 125.04% 106.31% 146.72%
2014 108.82% 71.35% 106.28% 29.01% 75.73%
2013 35.75% 27.73% 34.07% 86.72% 41.89%
2012 36.89% 48.64% 60.53% 73.1% 52.69%
2011 0.0% 63.24%

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.